Government-Owned Inventions; Availability for Licensing, 20928-20929 [E8-8213]
Download as PDF
<![CDATA[
20928
Federal Register / Vol. 73, No. 75 / Thursday, April 17, 2008 / Notices
Satisfaction Surveys: Reinstatement:
The information collected in these
surveys will be used by the Center for
Scientific Review management and
personnel: (1) To assess the quality of
the modified operations and processes
now used by CSR to review grant
applications; (2) To assess the quality of
service provided by CSR to our
customers; (3) To enable identification
of the most promising biomedical
research that will have the greatest
impact on improving public health by
using a peer review process that is fair,
unbiased from outside influence, timely,
and (4) To develop new modes of
operation based on customer need and
customer feedback about the efficacy of
implemented modifications. These
surveys, which will be both quantitative
and qualitative, are designed to assess
the quality of services we provide to our
major external customers. Customers
include the research scientists who
submit applications for grant funding to
NIH. Those grant applications are
reviewed and ranked by the grant
scientific peer review study groups’
members and chairs. These surveys will
almost certainly lead to quality
improvement activities that will
enhance and/or streamline CSR’s
operations. Our partners include current
grant scientific peer review study
groups’ members and chairs.
Frequency of Response: On occasion.
Affected Public: Scientific peer review
study groups’ members and chairs, grant
applicants, other members of the
research community.
Type of Respondents: Adult scientific
professionals.
ESTIMATES OF ANNUALIZED HOUR BURDEN
Annual
number of respondents
Number of
responses per
respondent
Annual
average burden
per response
(hours)
Focus Groups ..............................................................................................
Mail/telephone/e-mail Surveys .....................................................................
75
5,000
1
1
2.5
0.25
Annual Total .........................................................................................
5,075
sroberts on PROD1PC64 with NOTICES
Instrument/activity
Request For Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the function of the
agency, including whether the
information will have practical utility;
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) Ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
Ways to minimize the burden of the
collection of information on those who
are to respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
For Further Information Contact: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact Dr. Andrea
Kopstein, Director of Planning,
Analysis, and Evaluation, Center for
Scientific Review, NIH, Room 3030,
6701 Rockledge Drive, Bethesda, MD
20892–7776, or call non-toll-free
number (301) 435–1133 or E-mail your
request, including your address to:
kopsteina@csr.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
VerDate Aug<31>2005
17:08 Apr 16, 2008
Jkt 214001
Dated: April 7, 2008.
Andrea Kopstein,
Director of Planning, Analysis, and
Evaluation.
[FR Doc. E8–8230 Filed 4–16–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
Total burden
hours per
annual collection
187.5
1,250
1,437.5
be required to receive copies of the
patent applications.
Engineered Human Antibody Constant
Domains (Nanoantibodies) as Scaffolds
for Binders
Description of Technology: The
invention describes conceptually novel
scaffolds based on engineered human
antibody constant domains
(nanoantibody scaffold). They are highly
soluble, very stable, monomeric, and
can be expressed at high levels.
Furthermore, large libraries are
generated from which binders to
antigens are selected and characterized.
Advantages:
The engineered antibody domains are
more stable compared to existing
domain antibodies.
The nanoantibodies are derived from
human sequences and are likely to have
minimal toxic and immunogenic effects.
The small size of the nanoantibodies
ensures efficient penetration in tissues
including solid tumors and lymphoid
tissues where HIV replicates, and also
efficient neutralization of viruses, e.g.
HIV, that have evolved to avoid
neutralization by naturally occurring
large size IgGs generated by the immune
system.
Applications: The nanoantibodies
have potential for diagnosis and
treatment of cancer and AIDS as well as
diseases of the immune systems and
other diseases.
Development Status: Proof of concept
experiments have been completed.
Inventor: Dimiter Dimitrov (NCI).
Patent Status: U.S. Provisional
Application No. 61/063,245 filed 31 Jan
E:\FR\FM\17APN1.SGM
17APN1
Federal Register / Vol. 73, No. 75 / Thursday, April 17, 2008 / Notices
2008 (HHS Reference No. E–003–2007/
0–US–01).
Licensing Status: Available for
exclusive and non-exclusive license.
Licensing Contact: Richard Rodriguez;
301–435–4013; rodrigr@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute Center for
Cancer Research Nanobiology Program
is seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize
nanoantibodies as therapeutics or
diagnostics including imaging agents.
Please contact John D. Hewes, PhD at
301–435–3121 or hewesj@mail.nih.gov
for more information.
sroberts on PROD1PC64 with NOTICES
Methods and Compositions for the
Diagnosis of Neuroendocrine Lung
Cancer
Description of Technology: The
technology relates to the use of cDNA
microarrays to facilitate the
identification of pulmonary
neuroendocrine tumors. In order to
identify molecular markers that could
be used to classify pulmonary tumors,
the inventors examined the gene
expression profiles of clinical samples
from patients with small cell lung
cancer (SCLC), large cell
neuroendocrine carcinoma (LCNEC),
and typical carcinoma (TC) tumors by
cDNA microarray analysis to detect
hybridization between cDNA from
tumor cells and DNA from a panel of
8,897 human genes. Gene expression
was found to be nonrandom and to
exhibit highly significant clustering that
divided the tumors into their assigned
World Health Organization (WHO)
classification with 100% accuracy. The
inventors concluded that pulmonary
neuroendocrine tumors could be
classified based on the genome-wide
expression profile of the clinical
samples without further manipulations.
Applications:
Method to differentiate three types of
pulmonary neuroendocrine tumors;
Method to diagnose pulmonary
neuroendocrine cancer;
Neuroendocrine Microarray
Advantages: Accurate, rapid, easy to
use diagnostic to stratify patients
according to pulmonary tumors
Development Status: The technology
is currently in the pre-clinical stage of
development.
Market:
An estimated 1,444,920 new cancer
diagnoses in the U.S. in 2007.
Cancer is the second leading cause of
death in United States.
It is estimated that the cancer
therapeutic market would double to $50
VerDate Aug<31>2005
17:08 Apr 16, 2008
Jkt 214001
billion a year in 2010 from $25 billion
in 2006.
Inventors: Curtis C. Harris et al. (NCI).
Relevant Publications: P He et al.
Identification of carboxypeptidase E and
g-glutamyl hydrolase as biomarkers for
pulmonary neuroendocrine tumors by
cDNA microarray. Human Pathol. 2004
Oct;35(10):1196–1209.
Patent Status: U.S. Patent Application
No. 10/533,459 filed 02 May 2005 (HHS
Reference No. E–248–2002/0–US–04).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Jennifer Wong;
301–435–4633; wongje@mail.nih.gov
Dated: April 8, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E8–8213 Filed 4–16–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of federally
funded research and development.
Foreign patent applications are filed on
selected inventions to extend market
coverage for companies and may also be
available for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Substituted 3,6-diphenyl-7H-[1,2,4]
triazolo[3,4-b] [1,3,4] Thiadiazines as
Potent Inhibitors of PDE4A, PDE4B, and
PDE4D
Description of Technology:
Phosphodiesterase 4 (PDE4) is a major
cAMP-metabolizing enzyme found in
immune and inflammatory cells, airway
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
20929
smooth muscle, and pulmonary nerves.
It plays a significant role within the
inflammatory responses associated with
asthma and chronic obstructive
pulmonary disease (COPD) and its
modulation has been linked to memory
enhancement and depression. Due to its
widespread therapeutic potential, PDE4
inhibitors are highly sought after agents
for treating numerous disease states.
While several PDE4 inhibitors have
already advanced into clinical settings,
unfavorable side effects including
emesis, nausea, and abdominal pain
emphasize the need for novel
chemotypes with potent and selective
PDE4 inhibition.
This technology describes a series of
substituted 3,6-diphenyl-7H-[1,2,4]
triazolo[3,4-b] [1,3,4] thiadiazines that
act as inhibitors of PDE4. This core
structure represents a novel chemotype
within extensive classes of PDE4
inhibitors and the structure activity
relationships of these PDE4 inhibitors
identify key binding sites and
substitutions critical to the functionality
for potent PDE4 inhibition. Selectivity
of this novel chemotype shows weak
inhibitory potency against nine PDE
isoforms excluding PDE4 and strong
inhibitory potency against PDE4A,
PDE4B, and PDE4D. In a selectivity
comparison study, the novel chemotype
performs better than the PDE4 inhibitor
in clinical development. Subtypeselective PDE4 inhibitors are becoming
increasingly more important as new
research shows that independent PDE
isoforms have differential effects on
cells.
Applications: Treatment of numerous
diseases associated with PDE4 including
asthma, COPD, inflammatory bowel
disease, and other anti-inflammatory
diseases with other possible treatments
including depression and psychosis.
Development Status: Pre-clinical.
Publication: AP Skoumbourdis et al.
Identification of a potent new
chemotype for the selective inhibition of
PDE4. Bioorg Med Chem Lett. 2008 Feb
15;18(4):1297–1303.
Inventors: Craig J. Thomas et al.
(NHGRI).
Patent Status: U.S. Provisional
Application No. 61/020,079 filed 09 Jan
2008 (HHS Reference No. E–055–2008/
0–US–01).
Licensing Status: Available for
licensing.
Licensing Contact: Fatima Sayyid,
M.H.P.M.; 301–435–4521;
Fatima.Sayyid@nih.hhs.gov.
E:\FR\FM\17APN1.SGM
17APN1
]]>Agencies
[Federal Register Volume 73, Number 75 (Thursday, April 17, 2008)]
[Notices]
[Pages 20928-20929]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-8213]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Engineered Human Antibody Constant Domains (Nanoantibodies) as
Scaffolds for Binders
Description of Technology: The invention describes conceptually
novel scaffolds based on engineered human antibody constant domains
(nanoantibody scaffold). They are highly soluble, very stable,
monomeric, and can be expressed at high levels. Furthermore, large
libraries are generated from which binders to antigens are selected and
characterized.
Advantages:
The engineered antibody domains are more stable compared to
existing domain antibodies.
The nanoantibodies are derived from human sequences and are likely
to have minimal toxic and immunogenic effects.
The small size of the nanoantibodies ensures efficient penetration
in tissues including solid tumors and lymphoid tissues where HIV
replicates, and also efficient neutralization of viruses, e.g. HIV,
that have evolved to avoid neutralization by naturally occurring large
size IgGs generated by the immune system.
Applications: The nanoantibodies have potential for diagnosis and
treatment of cancer and AIDS as well as diseases of the immune systems
and other diseases.
Development Status: Proof of concept experiments have been
completed.
Inventor: Dimiter Dimitrov (NCI).
Patent Status: U.S. Provisional Application No. 61/063,245 filed 31
Jan
[[Page 20929]]
2008 (HHS Reference No. E-003-2007/0-US-01).
Licensing Status: Available for exclusive and non-exclusive
license.
Licensing Contact: Richard Rodriguez; 301-435-4013;
rodrigr@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute
Center for Cancer Research Nanobiology Program is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize nanoantibodies
as therapeutics or diagnostics including imaging agents. Please contact
John D. Hewes, PhD at 301-435-3121 or hewesj@mail.nih.gov for more
information.
Methods and Compositions for the Diagnosis of Neuroendocrine Lung
Cancer
Description of Technology: The technology relates to the use of
cDNA microarrays to facilitate the identification of pulmonary
neuroendocrine tumors. In order to identify molecular markers that
could be used to classify pulmonary tumors, the inventors examined the
gene expression profiles of clinical samples from patients with small
cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC),
and typical carcinoma (TC) tumors by cDNA microarray analysis to detect
hybridization between cDNA from tumor cells and DNA from a panel of
8,897 human genes. Gene expression was found to be nonrandom and to
exhibit highly significant clustering that divided the tumors into
their assigned World Health Organization (WHO) classification with 100%
accuracy. The inventors concluded that pulmonary neuroendocrine tumors
could be classified based on the genome-wide expression profile of the
clinical samples without further manipulations.
Applications:
Method to differentiate three types of pulmonary neuroendocrine
tumors;
Method to diagnose pulmonary neuroendocrine cancer;
Neuroendocrine Microarray
Advantages: Accurate, rapid, easy to use diagnostic to stratify
patients according to pulmonary tumors
Development Status: The technology is currently in the pre-clinical
stage of development.
Market:
An estimated 1,444,920 new cancer diagnoses in the U.S. in 2007.
Cancer is the second leading cause of death in United States.
It is estimated that the cancer therapeutic market would double to
$50 billion a year in 2010 from $25 billion in 2006.
Inventors: Curtis C. Harris et al. (NCI).
Relevant Publications: P He et al. Identification of
carboxypeptidase E and [gamma]-glutamyl hydrolase as biomarkers for
pulmonary neuroendocrine tumors by cDNA microarray. Human Pathol. 2004
Oct;35(10):1196-1209.
Patent Status: U.S. Patent Application No. 10/533,459 filed 02 May
2005 (HHS Reference No. E-248-2002/0-US-04).
Licensing Status: Available for exclusive or non-exclusive
licensing.
Licensing Contact: Jennifer Wong; 301-435-4633; wongje@mail.nih.gov
Dated: April 8, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E8-8213 Filed 4-16-08; 8:45 am]
BILLING CODE 4140-01-P
